Compare ABCL & ODC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABCL | ODC |
|---|---|---|
| Founded | 2012 | 1941 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Miscellaneous manufacturing industries |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2020 | 1994 |
| Metric | ABCL | ODC |
|---|---|---|
| Price | $5.63 | $83.71 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $8.40 | N/A |
| AVG Volume (30 Days) | ★ 8.2M | 69.3K |
| Earning Date | 05-11-2026 | 06-04-2026 |
| Dividend Yield | N/A | ★ 1.13% |
| EPS Growth | 10.91 | ★ 50.45 |
| EPS | N/A | ★ 1.69 |
| Revenue | $75,128,000.00 | ★ $485,572,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $21.85 | N/A |
| P/E Ratio | ★ N/A | $49.72 |
| Revenue Growth | ★ 160.56 | 10.97 |
| 52 Week Low | $2.53 | $45.61 |
| 52 Week High | $6.79 | $85.70 |
| Indicator | ABCL | ODC |
|---|---|---|
| Relative Strength Index (RSI) | 55.07 | 70.19 |
| Support Level | $5.34 | $70.50 |
| Resistance Level | $5.63 | N/A |
| Average True Range (ATR) | 0.56 | 2.67 |
| MACD | 0.05 | 0.48 |
| Stochastic Oscillator | 56.84 | 88.15 |
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups, namely the Retail and Wholesale Products Group, which derives maximum revenue, and the Business-to-Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.